Home
Home
Contact
Careers
Terms and Conditions
Privacy Policy
Cookie Policy
YouTube
X
LinkedIn
About Arcturus
RNA Medicines
Technologies
Pipeline
Clinical Trials
Business Development
Publications
Investor Relations

Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, noninferiority trial

December 21, 2023

Home
Contact
Careers
Terms and Conditions
Privacy Policy
Cookie Policy
YouTube
X
LinkedIn
© 2026 Arcturus Therapeutics, Inc.